Wearable Sensors to Study Low Blood Sugar in Type 1 Diabetes
Tests wearable glucose and smartwatch sensors in adults with type 1 diabetes.
Key facts
- Who runs it
- University of California, San Diego
- Where
- La Jolla, United StatesSee the site
- Trial code
- Registry title
- Using Wearable Sensors To Understand Low Blood Sugar in Type 1 Diabetes
- Status
- Not yet recruiting
- People taking part
- 20 people, planned
- Started
- 1 Feb 2025
- Planned end
- 30 Jun 2026
- Type of study
- Interventional
- Treatments tested
- Hyperglycemic clamp
- Record updated
- 10 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 who have had type 1 diabetes for more than 2 years. They will wear a glucose sensor and a smartwatch for 4 weeks.
- Age
- 18 to 75 years old
- Sex
- Men and women can join.
- Disease stage
- Type 1 diabetes for more than 2 years, with A1c above 7% (53 mmol/mol) and up to 10% (86 mmol/mol), and eGFR of 60 mL/min/1.73m² or more.
- Earlier treatment
- People must use a hybrid closed loop, a standard pump, or multiple daily injections. They must not have taken diabetes medicines other than insulin within the last month.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Severe low blood sugar or DKA within the last 3 months
- Currently using beta-blockers
- Adrenal insufficiency
- History of pancreatitis, medullary thyroid carcinoma or liver disease
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Men and women between the ages of 18 and 75 years old, inclusive, at the time of screening
- Females of non-childbearing potential must be ≥ 1 year post-menopausal or documented as being surgically sterile. Females of childbearing potential must agree to use two methods of contraception during the entire study
- Diagnosed with Type 1 diabetes >2-year duration based on clinical history or as defined by the current American Diabetes Association (ADA) criteria
- Using hybrid closed loop, standard pump, or multiple daily injections
- Able to use a Continuous Glucose Monitoring (CGM) device
- A1c > 7% and ≤ 10%:
- eGFR ≥ 60 mL/min/1.73m²
- BMI 18.5-35.0 kg/m2
- Able to provide written informed consent approved by an Institutional Review Board (IRB)
Who cannot take part
- Currently using beta-blockers
- History or evidence of clinically significant disorder or condition that, in the opinion of the Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion
- History of pancreatitis, medullary thyroid carcinoma or liver disease:
- Current or recent (within 1 month of screening) use of diabetes medications other than insulin; (examples include GLP-1, RA, SGLT-2i, Pramlintide, Metformin)
- Any other condition(s) that might reduce the chance of obtaining study data, or that might cause safety concerns, or that might compromise the ability to give truly informed consent
- Adrenal insufficiency diagnosis
- Clinically significant diagnosis of anemia (Hemoglobin < 9 g/dl at screening)
- Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations of plasma, packed RBCs, platelets or quantities less than 500 mL are allowed at investigator discretion
- Body Mass Index (BMI) < 18.5 kg/m2 and/or weight <50kg
- Body Mass Index (BMI) > 35 kg/m2
- Women who are pregnant or lactating/breastfeeding
- Unable or unwilling to follow the study protocol or who are non-compliant with screening appointments or study visits
- Severe hypoglycemic events or DKA within 3 months
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- University of California, San Diego - ACTRILa Jolla, United StatesContact: Program ManagerNot yet recruiting
About the trial
What the trial wants to find out
This is a single-site study using wearable sensor technology (CGM and smartwatch) to better explain low blood sugars in patients living with type 1 diabetes.
Read full original descriptionShow less
Up to 20 participants with T1D will wear a continuous glucose monitor (CGM) and a smartwatch to collect information about hypoglycemia (low blood sugar), heart rate variability (HRV), and sleep for 4 weeks. The main goal is to create a hypoglycemia risk score using wearable sensor metrics that can be easily applied to all patients with T1D to identify those at greater risk of hypoglycemia.
The group in the trial
- Wearable Sensor ArmOther group
The intervention is the hyperglycemic clamp. All participants will complete the clamp.
Treatment: Hyperglycemic clamp
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessment of Impaired Counterregulatory Hormones and Cardiovascular Risk Using Modern Wearable Sensors in People Living With Type 1 Diabetes.
- Plain-language title
- Wearable Sensors to Study Low Blood Sugar in Type 1 DiabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06727071, who can take part
- Record updated
- 10 December 2024